MicroRNA silencing of tumor suppressor DLC‐1 promotes efficient hepatitis C virus replication in primary human hepatocytes

Krishna Banaudha, Michael Kaliszewski, Tamara Korolnek, Liliana Florea, Man Lung Yeung, Kuan‐Teh Jeang, Ajit Kumar – 30 September 2010 – MicroRNAs (miRNAs) are approximately 22‐nucleotide noncoding RNAs that constitute silencers of target gene expression. Aberrant expression of miRNA has been linked to a variety of cancers, including hepatocellular carcinoma (HCC). Hepatitis C virus (HCV) infection is considered a major cause of chronic liver disease and HCC, although the mechanism of virus infection–associated hepatocarcinogenesis remains unclear.

Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy

Peter J. Lewindon, Ross W. Shepherd, Meagan J. Walsh, Ristan M. Greer, Richard Williamson, Tamara N. Pereira, Kieran Frawley, Scott C. Bell, Jeffery L. Smith, Grant A. Ramm – 30 September 2010 – Cystic fibrosis liver disease (CFLD), which results from progressive hepatobiliary fibrosis, is an important cause of morbidity and mortality, but it is difficult to identify before portal hypertension (PHT) ensues.

Enteric dysbiosis associated with a mouse model of alcoholic liver disease

Arthur W. Yan, Derrick E. Fouts, Johannes Brandl, Peter Stärkel, Manolito Torralba, Eckart Schott, Hide Tsukamoto, Karen E. Nelson, David A. Brenner, Bernd Schnabl – 30 September 2010 – The translocation of bacteria and bacterial products into the circulation contributes to alcoholic liver disease. Intestinal bacterial overgrowth is common in patients with alcoholic liver disease. The aims of our study were to investigate bacterial translocation, changes in the enteric microbiome, and its regulation by mucosal antimicrobial proteins in alcoholic liver disease.

p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3‐kinase/AKT/hypoxia‐inducible factor‐1α pathways

Jing Fu, Yao Chen, Jie Cao, Tao Luo, You‐Wen Qian, Wen Yang, Yi‐Bin Ren, Bo Su, Guang‐Wen Cao, Yuan Yang, Yi‐Qun Yan, Feng Shen, Meng‐Chao Wu, Gen‐Sheng Feng, Hong‐Yang Wang – 30 September 2010 – The overall survival of patients with hepatocellular carcinoma (HCC) remains poor, and the molecular mechanisms underlying HCC progression and aggressiveness are unclear. Here, we report that increased expression of p28GANK (Gankyrin, PSMD10, or p28) in human HCC predicts poor survival and disease recurrence after surgery.

Reply

Doris Wagner, Daniela Kniepeiss, Florian Iberer, Astrid Fahrleitner‐Pammer, Peter Kornprat, Karlheinz Tscheliessnigg – 28 September 2010

The immunosuppressive pipeline: Meeting unmet needs in liver transplantation

Nazia Selzner, David R. Grant, Itay Shalev, Gary A. Levy – 28 September 2010 – Liver transplantation is now recognized as the treatment of choice for end‐stage liver failure. Its success can be attributed largely to the generation of selective immunosuppressive agents, which have resulted in a dramatic reduction in the incidence of acute rejection and improvements in the short‐ and long‐term outcomes of patients.

Subscribe to